Universe Pharmaceuticals INC revenue by segment UPC
Universe Pharmaceuticals INC splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Sep 30, 2025 was Revenue From Sales Of Selfmanufactured TCMD Products at $13.3 billion, 74% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
|---|---|---|---|---|---|
| Revenue |
17,859
|
23,024
|
32,309
|
40
|
48
|
| Revenue From Sales Of Selfmanufactured TCMD Products |
13,261
-5.5%
share 74.3%
|
14,026
-24.5%
share 60.9%
|
18,573
share 57.5%
|
—
|
—
|
| Revenue From Sales Of Thirdparty Products |
4,598
-48.9%
share 25.7%
|
8,998
-34.5%
share 39.1%
|
13,736
share 42.5%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPC (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- China
- Headquarters
- Ji'An, Jiangxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1809616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.